$CIM Balance Sheet | Understand Stock

$CIM

$8.39 +$0.00 (0.0%) Close

$CIM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of financial condition

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Cash and cash equivalents
Non-Agency RMBS, at fair value (net of allowance for credit losses of $53 million and $43 million, respectively)
Variable Interest Entities, Primary Beneficiary
Total non-Agency RMBS, at fair value (net of allowance for credit losses of $53 million and $43 million, respectively)
Agency RMBS, at fair value
Agency CMBS, at fair value
Agency MBS, at fair value
Loans held for investment, at fair value
Variable Interest Entities, Primary Beneficiary
Total loans held for investment, at fair value
Receivable for investments sold
Loans held-for-sale, at fair value
Accrued interest receivable
Variable Interest Entities, Primary Beneficiary
Total accrued interest receivable
Other assets
Variable Interest Entities, Primary Beneficiary
Total other assets
Interests in MSR financing receivables
Variable Interest Entities, Primary Beneficiary
Total interests in MSR financing receivables
Derivatives, at fair value, net
Assets
Variable Interest Entities, Primary Beneficiary
Total assets
Liabilities:
Secured financing agreements ($8.6 billion and $7.4 billion pledged as collateral, respectively, and includes $284 million and $299 million at fair value, respectively)
Securitized debt, collateralized by Non-Agency RMBS ($195 million and $210 million pledged as collateral, respectively)
Variable Interest Entities, Primary Beneficiary
Total securitized debt, collateralized by Non-Agency RMBS ($195 million and $210 million pledged as collateral, respectively)
Securitized debt at fair value, collateralized by Loans held for investment ($7.5 billion and $9.4 billion pledged as collateral, respectively)
Variable Interest Entities, Primary Beneficiary
Total securitized debt at fair value, collateralized by Loans held for investment ($7.5 billion and $9.4 billion pledged as collateral, respectively)
Long term debt
Payable for investments purchased
Accrued interest payable
Variable Interest Entities, Primary Beneficiary
Total accrued interest payable
Dividends payable
Accounts payable and other liabilities
Variable Interest Entities, Primary Beneficiary
Total accounts payable and other liabilities
Derivatives, at fair value, net
Variable Interest Entities, Primary Beneficiary
Total liabilities
Stockholders’ Equity:
Preferred Stock, par value of $0.01 per share, 100,000,000 shares authorized:
Series A Preferred Stock
Series B Preferred Stock
Series C Preferred Stock Par Value
Series D Preferred Stock
Common stock: par value $0.01 per share; 166,666,667 shares authorized, 83,711,380 and 83,402,145 shares issued and outstanding, respectively
Additional paid-in-capital
Accumulated other comprehensive income
Cumulative earnings
Cumulative distributions to stockholders
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments